Article PDF first page preview

First page of Case Report Series and Mini Review on Tuberculosis in IVF-ET Pregnancies: A Call for Vigilant Monitoring and Early Intervention

Background: The risk of tuberculosis during pregnancy is significantly increased, and untimely Mycobacterium tuberculosis (M. tuberculosis) treatment during pregnancy increases the risk of perinatal complications and poor fetal prognosis. Hormonal use in vitro fertilization and embryo transfer (IVF-ET) promotes the growth of M. tuberculosis, leading to more severe disease and adverse pregnancy outcomes. However, its clinical characteristics and possible mechanisms of TB infection in pregnant women who conceive by IVF-ET remain unclear. Therefore, we report three cases of young pregnant women diagnosed with TB after IVF-ET and describe their diagnosis and treatment. Case presentation: Three young women (age: 26–31 years) diagnosed with primary infertility underwent IVF-ET treatment. They lacked a history of TB or manifestations of activated TB before transplantation. After presenting with fever, cough, and headache at 5–12 weeks of pregnancy, they were diagnosed with miliary TB, disseminated TB, and tuberculous meningitis, respectively. Initially, the patients were on a daily fixed-dose combination of first-line anti-TB treatment (ATT), which comprised rifampicin, isoniazid, pyrazinamide, and ethambutol, followed by medication adjustment during treatment for 6–12 months. Although all fetuses were lost, the patients achieved optimal outcomes after timely ATT. Conclusions: This report demonstrates the increased risk of TB in pregnant women who conceive by IVF-ET. Therefore, it is important to carefully monitor these women even if they lack a history of or exposure to TB. Accordingly, prompt diagnosis and treatment of TB in these patients is necessary to optimize patient outcomes.

Journal Section:
Novel Insights from Clinical Practice
This content is only available via PDF.
S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.